DCT

1:26-cv-00980

Eli Lilly & Co v. Galenicum Health Slu

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00980, D. Del., 08/06/2026
  • Venue Allegations: Venue is asserted as proper on the basis that Defendant is a foreign corporation, which may be sued in any judicial district.
  • Core Dispute: Plaintiff alleges that Defendant's submission of Abbreviated New Drug Applications (ANDAs) to the FDA for generic versions of Plaintiff's Mounjaro® and Zepbound® products infringes nine U.S. patents covering compositions and methods of using the active ingredient tirzepatide.
  • Technical Context: The technology relates to pharmaceutical formulations and therapeutic uses of tirzepatide, a dual GIP/GLP-1 receptor co-agonist that has achieved significant market success for the treatment of type 2 diabetes and obesity.
  • Key Procedural History: This action was initiated under the Hatch-Waxman Act following Plaintiff's receipt of "Notice Letters" from Defendant, which included Paragraph IV Certifications asserting that the asserted patents are invalid, unenforceable, or will not be infringed by the proposed generic products. All asserted patents are listed in the FDA's Orange Book for either Mounjaro®, Zepbound®, or both.

Case Timeline

Date Event
2018-06-22 Priority Date for '820 and '623 Patents
2018-07-23 Priority Date for '987 Patent
2022-05-13 FDA approval of Mounjaro®
2022-06-14 '820 Patent Issued
2023-11-08 FDA approval of Zepbound®
2024-03-05 '623 Patent Issued
2025-05-13 '987 Patent Issued
2025-07-01 '382 Patent Issued
2025-10-28 '755, '756, and '758 Patents Issued
2026-05-05 '740 Patent Issued
2026-05-19 '404 Patent Issued
2026-07-08 Date of first Galenicum Notice Letter
2026-07-09 Lilly's receipt of first Galenicum Notice Letter
2026-08-06 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,357,820: GIP/GLP1 Agonist Compositions (Issued Jun. 14, 2022)

The Invention Explained

  • Problem Addressed: The patent background describes a desire for compositions of the GIP/GLP1 co-agonist peptide tirzepatide that provide acceptable stability and an acceptable patient injection site experience U.S. Patent No. 11,357,820, col. 1:24-29 The patent notes that certain excipients, such as NaCl and citrate, have been associated with painful stinging at the injection site U.S. Patent No. 11,357,820, col. 4:8-13
  • The Patented Solution: The patent claims to solve this problem by providing a specific pharmaceutical composition comprising tirzepatide, NaCl, and dibasic sodium phosphate U.S. Patent No. 11,357,820, col. 1:21-23 This combination is described as providing commercially acceptable shelf-life stability, in-use stability, and an acceptable patient injection site experience U.S. Patent No. 11,357,820, col. 1:23-26
  • Technical Importance: Creating a stable, injectable peptide formulation that is also well-tolerated by patients is critical for the commercial viability of chronic subcutaneous therapies like tirzepatide U.S. Patent No. 11,357,820, col. 4:5-8

Key Claims at a Glance

  • The complaint asserts at least independent claim 1 Compl. ¶50
  • Claim 1 Elements:
    • A pharmaceutical composition comprising tirzepatide, or a pharmaceutically acceptable salt thereof;
    • NaCl at a concentration from 6.2 mg/mL to 9.5 mg/mL; and
    • dibasic sodium phosphate.
  • The complaint reserves the right to assert additional claims Compl. ¶51

U.S. Patent No. 11,918,623: GIP/GLP1 Agonist Compositions (Issued Mar. 5, 2024)

The Invention Explained

  • Problem Addressed: Similar to the '820 Patent, the background of the '623 Patent addresses the need for stable, patient-acceptable compositions of tirzepatide for treating conditions like diabetes and obesity U.S. Patent No. 11,918,623, col. 1:19-35
  • The Patented Solution: The '623 Patent claims a method of treating obesity by administering an effective dose of a pharmaceutical composition containing tirzepatide and specific excipients within defined concentration ranges U.S. Patent No. 11,918,623, claim 1 The claimed composition includes tirzepatide, dibasic sodium phosphate, NaCl, and optionally phenol, all within specified concentrations U.S. Patent No. 11,918,623, col. 2:44-64
  • Technical Importance: This patent links specific formulation parameters to a method of therapeutic use, aiming to protect not just the drug product itself but also its approved method for treating obesity U.S. Patent No. 11,918,623, col. 3:5-12

Key Claims at a Glance

  • The complaint asserts at least independent claim 1 Compl. ¶66
  • Claim 1 Elements:
    • A method of treating obesity comprising administering to a human in need thereof an effective dose of a pharmaceutical composition comprising tirzepatide, or a pharmaceutically acceptable salt thereof;
    • wherein the tirzepatide concentration is from about 5 mg/mL to about 30 mg/mL;
    • dibasic sodium phosphate is from about 0.67 to about 2.68 mg/mL;
    • NaCl at a concentration from about 6.2 mg/mL to about 9.5 mg/mL; and
    • optionally comprising from about 3.0 mg/mL to about 7.0 mg/mL phenol.
  • The complaint reserves the right to assert additional claims Compl. ¶67

U.S. Patent No. 12,295,987: Methods of Using a GIP/GLP1 Co-agonist for Diabetes (Issued May 13, 2025)

  • Technology Synopsis: This patent is directed to methods of treating type 2 diabetes using a GIP:GLP-1 peptide with a specific receptor agonist potency ratio. The method involves a multi-step dose escalation regimen, starting with a first dose and administering subsequent higher doses over defined time periods U.S. Patent No. 12,295,987, claim 1
  • Asserted Claims: At least independent claim 1 is asserted Compl. ¶84
  • Accused Features: The complaint alleges that the proposed labeling for the generic product instructs and encourages the claimed multi-step dosing method for treating type 2 diabetes Compl. ¶85

U.S. Patent No. 12,343,382: Methods of Using a GIP/GLP1 Co-agonist for Therapy (Issued Jul. 1, 2025)

  • Technology Synopsis: This patent covers methods of treating type 2 diabetes and improving weight management through a dosing regimen of tirzepatide. The method involves administering specific "escalation" doses followed by specific "maintenance" doses (U.S. Patent No. 12,343,382, claims 1; U.S. Patent No. 12,343,382, claim 11).
  • Asserted Claims: At least independent claims 1 and 11 are asserted Compl. ¶¶103-106
  • Accused Features: The complaint alleges the proposed labeling for the generic products instructs and encourages the claimed escalation and maintenance dosing regimens for treating type 2 diabetes and improving weight management Compl. ¶104 Compl. ¶106

U.S. Patent No. 12,453,755: GIP/GLP1 Agonist Compositions (Issued Oct. 28, 2025)

  • Technology Synopsis: Similar to the '623 Patent, this patent is directed to a method of treating diabetes by administering a specific pharmaceutical composition containing tirzepatide, dibasic sodium phosphate, NaCl, and optionally phenol within defined concentration ranges.
  • Asserted Claims: At least independent claim 1 is asserted Compl. ¶126
  • Accused Features: The complaint alleges the proposed labeling for the generic product instructs and encourages the administration of the claimed composition for treating diabetes Compl. ¶127

U.S. Patent No. 12,453,756: GIP/GLP1 Agonist Compositions (Issued Oct. 28, 2025)

  • Technology Synopsis: This patent claims a pharmaceutical composition comprising tirzepatide and a specific concentration range of NaCl, where the composition has a defined pH range of about 6.5 to 7.5.
  • Asserted Claims: At least independent claim 1 is asserted Compl. ¶144
  • Accused Features: The complaint alleges the proposed generic products are pharmaceutical compositions that meet the claim limitations regarding tirzepatide, NaCl concentration, and pH Compl. ¶145

U.S. Patent No. 12,453,758: Methods of Using a GIP/GLP1 Co-agonist for Diabetes (Issued Oct. 28, 2025)

  • Technology Synopsis: This patent covers a method of improving weight management using a GIP:GLP-1 peptide with a specific receptor agonist potency ratio. The method involves a multi-step dose escalation regimen.
  • Asserted Claims: At least independent claim 1 is asserted Compl. ¶161
  • Accused Features: The complaint alleges the proposed labeling for the generic product instructs and encourages the claimed multi-step dosing method for improving weight management Compl. ¶162

U.S. Patent No. 12,616,740: Methods of Using a GIP/GLP1 Co-agonist for Therapy (Issued May 5, 2026)

  • Technology Synopsis: This patent claims methods for treating type 2 diabetes and obesity by administering tirzepatide in a specific once-weekly, multi-step dose escalation and maintenance regimen.
  • Asserted Claims: At least independent claims 1 and 6 are asserted Compl. ¶179 Compl. ¶181
  • Accused Features: The complaint alleges the proposed labeling for the generic products instructs and encourages the claimed dosing regimens for treating type 2 diabetes and obesity Compl. ¶180 Compl. ¶182

U.S. Patent No. 12,629,404: GIP/GLP1 Agonist Compositions (Issued May 19, 2026)

  • Technology Synopsis: This patent claims a pharmaceutical composition comprising tirzepatide and NaCl within a specific concentration range, having a defined pH range, and being "free of preservative."
  • Asserted Claims: At least independent claim 1 is asserted Compl. ¶202
  • Accused Features: The complaint alleges the proposed generic products are compositions that meet all limitations of claim 1, including being free of preservative Compl. ¶203

III. The Accused Instrumentality

  • Product Identification: The accused instrumentalities are Defendant's "Proposed ANDA Products" corresponding to Abbreviated New Drug Application (ANDA) Nos. 221515 and 221514 Compl. ¶1
  • Functionality and Market Context: The Proposed ANDA Products are generic versions of Plaintiff's Mounjaro® and Zepbound® products Compl. ¶1 They are described as sterile solutions of tirzepatide in various strength autoinjectors (2.5, 5, 7.5, 10, 12.5, and 15 mg/0.5 mL) for subcutaneous use Compl. ¶1 Compl. ¶18 The complaint alleges that these products, if approved, would be marketed as direct competitors to Mounjaro® and Zepbound® for improving glycemic control, chronic weight management, and treating obstructive sleep apnea Compl. ¶1 Compl. ¶¶1-2

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

11,357,820 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A pharmaceutical composition comprising tirzepatide, or a pharmaceutically acceptable salt thereof; The complaint alleges that the Proposed ANDA Products are pharmaceutical compositions that comprise tirzepatide or a pharmaceutically acceptable salt thereof. ¶51 col. 3:21-32
NaCl at a concentration from 6.2 mg/mL to 9.5 mg/mL; The complaint alleges that the Proposed ANDA Products contain NaCl at a concentration within the claimed range of 6.2 mg/mL to 9.5 mg/mL. ¶51 col. 1:33-34
and dibasic sodium phosphate. The complaint alleges that the Proposed ANDA Products contain dibasic sodium phosphate. ¶51 col. 1:41-45
  • Identified Points of Contention:
    • Scope Question: A potential point of contention may be whether the term "about" as used in some dependent claims provides a scope that is definite and distinct from the precise ranges of the independent claim.
    • Technical Question: The central factual question will be whether the final formulation of Galenicum's Proposed ANDA Products, as detailed in its ANDA, contains NaCl and dibasic sodium phosphate within the concentration ranges specified by the asserted claims.

11,918,623 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating obesity comprising administering to a human in need thereof an effective dose of a pharmaceutical composition comprising tirzepatide, or pharmaceutically acceptable salt thereof... The complaint alleges that Defendant is seeking approval for a proposed label that "instructs and encourages treating obesity" by administering the claimed composition. This forms the basis for an inducement of infringement allegation. ¶67 col. 3:5-12
...wherein the tirzepatide concentration is from about 5 mg/mL to about 30 mg/mL; dibasic sodium phosphate is from about 0.67 to about 2.68 mg/mL; NaCl at a concentration from about 6.2 mg/mL to about 9.5 mg/mL; and optionally comprising from about 3.0 mg/mL to about 7.0 mg/mL phenol. The complaint alleges that the composition described in the proposed labeling for the generic product meets the specific concentration limitations for tirzepatide, dibasic sodium phosphate, NaCl, and optional phenol. ¶67 col. 2:1-24
  • Identified Points of Contention:
    • Legal Question: The core issue for infringement of this method claim is inducement. The dispute will likely center on whether the language in the Defendant's proposed product label "instructs and encourages" the administration of the product for "treating obesity" in a manner that directly meets all the steps of the claimed method.
    • Technical Question: A factual dispute may arise over whether the composition detailed in the ANDA and its proposed label strictly meets all the claimed concentration ranges, including the optional presence and concentration of phenol.

V. Key Claim Terms for Construction

For the '820 Patent:

  • The Term: "dibasic sodium phosphate"
  • Context and Importance: This term is a required excipient in the claimed composition U.S. Patent No. 11,357,820, claim 1 Practitioners may focus on this term because the precise form of the phosphate buffer (e.g., anhydrous, heptahydrate) could be a point of non-infringement if the accused product uses a different form not explicitly covered or considered equivalent.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The claim language itself does not specify a hydration state, which may support an interpretation that covers any form of dibasic sodium phosphate that functions as a buffer.
    • Evidence for a Narrower Interpretation: The specification provides examples using "dibasic sodium phosphate heptahydrate" U.S. Patent No. 11,357,820, col. 5, TABLE 3, which could be used to argue for a narrower construction limited to the specific form disclosed in the embodiments.

For the '623 Patent:

  • The Term: "effective dose"
  • Context and Importance: This term is central to the method claim, defining the amount of the composition to be administered for "treating obesity" U.S. Patent No. 11,918,623, claim 1 Its construction is critical because infringement will depend on whether the dosage instructions on the accused product's label direct an "effective dose" for the claimed indication.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The term is not explicitly defined, which may support giving it the plain and ordinary meaning understood by a person of ordinary skill in the art-namely, an amount sufficient to produce a therapeutic effect for obesity.
    • Evidence for a Narrower Interpretation: The specification links specific dose amounts (e.g., 5, 10, 15, 20, 25, and 30 mg/mL) to the invention U.S. Patent No. 11,918,623, col. 2:19-21, which a defendant may argue limits the scope of "effective dose" to the ranges and specific dosing regimens disclosed in the patent.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges both active inducement and contributory infringement for all asserted patents. The primary basis for inducement is the allegation that Defendant's proposed product labeling will instruct and encourage healthcare providers and patients to use the generic products in an infringing manner, such as by administering a composition that meets the claims or by following a claimed dosing regimen Compl. ¶59 Compl. ¶75 Compl. ¶94 Contributory infringement is alleged on the basis that the proposed products are especially made or adapted for an infringing use and are not suitable for substantial non-infringing use Compl. ¶60 Compl. ¶78
  • Willful Infringement: The complaint alleges that Defendant had knowledge of the asserted patents at least due to their listing in the FDA's Orange Book and their inclusion in Defendant's Notice Letters Compl. ¶58 Compl. ¶74 Compl. ¶93 While not using the word "willful," the complaint requests a finding that this is an "exceptional case" and an award of attorneys' fees, which is the legal standard for post-AIA willful infringement Compl. p. 48, ¶(f)

VII. Analyst's Conclusion: Key Questions for the Case

  1. A central question will be one of claim scope: For the composition patents, will the court construe the claimed concentration ranges narrowly to the exact figures, or will the term "about" in dependent claims provide broader coverage? For the method patents, how will the court define an "effective dose" and the specific steps of the claimed dosing regimens?
  2. A key evidentiary question for the method claims will be one of inducement: What specific language exists in the Defendant's proposed product labels, and does that language rise to the level of actively encouraging or instructing infringement of the patented methods, as opposed to merely describing a potential use?
  3. A significant legal and factual issue will be whether Galenicum's proposed product formulations literally infringe the composition claims. This will likely involve a direct comparison of the formulation specified in Galenicum's ANDA with the limitations of claims in patents like the '820, '756, and '404 Patents, focusing on the exact identity and concentration of all claimed excipients.
Loading Complaint